Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lixadesiran + pixofisiran by Sirnaomics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC)....
Lixadesiran + pixofisiran by Sirnaomics for Hepatocellular Carcinoma: Likelihood of Approval
Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...
Lixadesiran + pixofisiran by Sirnaomics for Keloids: Likelihood of Approval
Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase II for Keloids. According to GlobalData, Phase...
Lixadesiran + pixofisiran by Sirnaomics for Abdominal Obesity: Likelihood of Approval
Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase I for Abdominal Obesity. According to GlobalData,...
Lixadesiran + pixofisiran by Sirnaomics for Solid Tumor: Likelihood of Approval
Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase I for Solid Tumor. According to GlobalData,...
Lixadesiran + pixofisiran by Sirnaomics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...
Lixadesiran + pixofisiran by Sirnaomics for Hypertrophic Scars: Likelihood of Approval
Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase II for Hypertrophic Scars. According to GlobalData,...
Lixadesiran + pixofisiran by Sirnaomics for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase II for Basal Cell Carcinoma (Basal Cell...